Market Overview

Biogen, Isis Pharmaceuticals Announce Strategic Collaboration

Related BIIB
The Week Ahead: IPOs, Earnings, And FDA Actions Provide Catalysts
34 Biggest Movers From Friday
Novo Nordisk: Still A Safe Bet Under One Condition (Seeking Alpha)

Biogen Idec (NASDAQ: BIIB) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the companies have entered into a broad, multi-year collaboration to leverage antisense technology to advance the treatment of neurological diseases. The agreement combines Biogen Idec's expertise in neurology with Isis' leadership in antisense technology to develop novel therapies to treat neurological disorders. This is the fourth collaboration between the two companies in the last two years.

"This strategic alliance with Isis builds on our existing relationship and combines the unique strengths of each partner to significantly advance the treatment of serious neurological diseases," said Douglas E. Williams, Ph.D., Biogen Idec's executive vice president of research and development. "Antisense is a validated technology that we believe will help build our pipeline of antisense, small molecule and biologics programs, strengthening our leadership in neurology."

Antisense technology is designed to alter a gene's function, silencing a mutation or activating a gene to compensate for an underlying genetic defect. When the

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global


Related Articles (BIIB + ISIS)

View Comments and Join the Discussion!